SecProbe.io

CORRESP
1
filename1.htm

1271 Avenue of the Americas | New York, New York 10020

Blankrome.com

July 13, 2023

VIA EDGAR

United States Securities

and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, D.C. 20549

Attention: Cindy Polynice

 Re: Adial Pharmaceuticals, Inc.

    Registration Statement on Form S-1

    Filed June 23, 2023

    File No. 333-272846

Dear Ms. Polynice:

On behalf of our client, Adial
Pharmaceuticals, Inc. (the “Company”), we submit this letter in response to comments from the staff (the “Staff”)
of the Securities and Exchange Commission (the “Commission”) contained in its letter dated July 7, 2023 (the “Comment
Letter”), relating to the above-referenced filings.

Set forth below in bold are
comments from the Comment Letter. For your convenience, each of the numbered paragraphs below corresponds to the numbered comment in the
Staff’s Comment Letter and includes the caption used in the Comment Letter. Immediately following each comment is the Company’s
response to that comment.

Registration Statement on Form S-1
filed June 23, 2023

Cover Page

1. We note that you are seeking to register 10,199,620 shares of common stock for resale, but you disclose
on page 4 that you only may issue 5,916,575 shares to Alumni Capital under the Purchase Agreement before obtaining shareholder approval
and you disclose on page 7 that “only 1,541,370 shares of common stock remain issuable at this time.” More specifically, we
note that all of the common shares you are seeking to register will not be duly authorized at the time of registration. Please revise
your registration statement so that the volume of common shares registered does not exceed the number of common shares that remain available
for issuance or otherwise advise.

Response: We have revised the registration
statement to register only 1,740,990 shares of common stock, consisting of the 1,541,370 shares issuable at this time and the 199,620
commitment shares already issued.

The Alumni Capital Transaction,
page 4

2. We note your disclosure that under your Purchase Agreement with Alumni Capital dated May 31, 2023, “[u]nder
the applicable rules of the Nasdaq, in no event may [you] issue more than 5,916,575 Shares... unless [you] obtain stockholder approval
to issue shares of Common Stock in excess of the Exchange Cap, provided further that the Exchange Cap does not apply to the extent the
purchase price is equal to or exceeds the Minimum Price (as defined in the Purchase Agreement).” Please revise your disclosure to
disclose the “Minimum Price” or otherwise advise.

Response: We have revised our
disclosure to disclose the Minimum Price.

United States Securities

and Exchange Commission

July 13, 2023

Page 2

Exhibits

3. Please revise the legal opinion filed as Exhibit 5.1. The opinion should not assume material facts underlying
the opinion. In this regard, we note that the opinion assumes that “there will be sufficient shares of Common Stock authorized but
unissued under the Certificate of Incorporation and not otherwise reserved for issuance.” However, this assumption goes to whether
the shares will be validly issued. See Item II.B.3.a. of Staff Legal Bulletin No. 19.

Response: We have revised the
legal opinion filed as Exhibit 5.1.

We remind you
that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments,
action or absence of action by the staff.

*****

Please contact me at (516)
457-4238 with any questions or further comments regarding the response to the Staff’s comments.

    Sincerely,

    /s/ Leslie Marlow

    Leslie Marlow